Neurology News and Research

Latest Neurology News and Research

Study finds depression as a risk factor for Alzheimer's disease

Depression is commonly reported in people with Alzheimer's disease and its precursor, mild cognitive impairment, with several studies suggesting having a history of major depression may nearly double your risk of developing dementia later in life. However, it has been unclear if depression is a symptom of the disease or a potential cause of the disease.

6 Jul 2010

Depression increases risk of developing dementia later in life

A new study shows that having depression may nearly double your risk of developing dementia later in life. The research will be published in the July 6, 2010, issue of Neurology-, the medical journal of the American Academy of Neurology.

6 Jul 2010

Depression and dementia may go hand in hand: Study

A new study has found that depressive disorders raise the risk of dementia. The findings of this study were published in the journal Neurology. The study involved nearly 1,000 people who were studied for up to 17 years. Those who were depressed when first examined almost doubled their risk for dementia and also increased their risk for Alzheimer's disease the study authors wrote.

5 Jul 2010

Quintiles announces strategic alliance agreement with UMMC as part of Prime Site program

Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University Malaya Medical Centre as part of its unique Prime Site program - an initiative focused on accelerating the development of new and more effective medicines.

5 Jul 2010

Two-day international Osteoarthritis Summit to be held in June 2011

Hospital for Special Surgery (HSS) plans to host a two-day international Osteoarthritis Summit in June 2011. The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together, for the first time, a truly comprehensive multidisciplinary group of world renowned scientists, thought-leaders and industry representatives from the United States, Canada, and Europe, to discuss all aspects of OA and develop a consensus document on future directions for OA research, prevention and treatment.

3 Jul 2010

Intellipharmaceutics provides update on generic version of Effexor XR

Intellipharmaceutics International Inc., today announced the following with regard to its generic drug commercialization activities.

3 Jul 2010

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

Endo Pharmaceuticals today announced the successful completion of the tender offer by its wholly owned subsidiary, HT Acquisition Corp., for all of the outstanding shares of common stock of HealthTronics, Inc..

3 Jul 2010

ClinTec International CRO expands US based operations with launch of New York office

UK-based Global Clinical Research Organisation (CRO), ClinTec International has unveiled a significant expansion into the US marketplace, with the launch of its New York office and the appointment of Susan Pavone, Associate Director of US Business Operations.

2 Jul 2010

Researchers identify gene abnormality for most common congenital birth defect, clubfoot

Although clubfoot is one of the most common congenital birth defects, few genetic causes have been found. Now, researchers at Washington University School of Medicine in St. Louis have found what they believe to be the most common cause of inherited clubfoot yet discovered.

2 Jul 2010

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Sun Pharma announced launch of generic Exelon, rivastigmine tartrate capsules for the US market. Earlier, USFDA had granted final approval for the Company's ANDA to market these products.

2 Jul 2010

Imbalance in neuroendocrine system linked to depression in MS patients: Study

Now, in the first such study in living humans, researchers at UCLA suggest a cause, and it's not psychological, but physical: atrophy of a specific region of the hippocampus, a critical part of the brain involved in mood and memory, among other functions.

2 Jul 2010

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

Andrew Lees, Professor of Neurology at University College London, is to be the first ever recipient of the Lord Brain Memorial Medal - awarded for the scientific contributions he has made to the field of movement disorders within the UK. He will receive the medal following his delivery of the inaugural Lord Brain Memorial Lecture; "Brainwashed by the Black Stuff," at Barts and The London Medical School on June 24, 2010.

1 Jul 2010

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

New research has identified the memory and brain scan tests that appear to predict best whether a person with cognitive problems might develop Alzheimer's disease. The research is published in the June 30, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology.

1 Jul 2010

Endo responds to FDA Complete Response letter for FORTESTA NDA

Endo Pharmaceuticals has submitted a complete response to the U.S. Food and Drug Administration (FDA) following the company's receipt of a Complete Response letter in October 2009 related to the New Drug Application (NDA) submission for FORTESTA™ (testosterone) 2% gel. The company's Class 2 resubmission is the next step in its intention to offer FORTESTA as a treatment option in the United States for men diagnosed with low testosterone (Low T), also known as hypogonadism. The FDA's review period for Class 2 resubmissions typically is six months.

1 Jul 2010

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Arena Pharmaceuticals, Inc. today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management, is intended for obese patients as well as overweight patients who have at least one weight-related co-morbid condition.

1 Jul 2010

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai Inc., the U.S. pharmaceutical operation of Tokyo-based Eisai Co., Ltd., announced today that it has entered into an agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., for exclusive U.S. rights to commercialize lorcaserin, a drug candidate for potential use in the treatment of obesity, including weight loss, for patients who are obese (Body Mass Index or BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related co-morbid condition.

1 Jul 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

30 Jun 2010

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

9th INT'L BIO FORUM & BIO EXPO JAPAN, organized by Reed Exhibitions Japan, will come back again as Asia's largest bio-event from June 30 - July 2, 2010. "Gene diagnosis" is one of the featured topics for this year.

30 Jun 2010

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

New long term data showed that Vimpat- (lacosamide) C-V provided sustained reduction in seizure frequency for up to five years when used as an add-on treatment for uncontrolled partial onset seizures in adults with epilepsy. In addition post-hoc exploratory analyses showed that adjunctive lacosamide treatment reduced partial-onset seizure frequency and improved responder rates when added to a broad range of antiepileptic drugs (AEDs) including both traditional sodium channel-blocking agents and those that act on non-sodium channel-targets.

30 Jun 2010

Neurology News and Research

Latest Neurology News and Research

Study finds depression as a risk factor for Alzheimer's disease

Depression increases risk of developing dementia later in life

Depression and dementia may go hand in hand: Study

Quintiles announces strategic alliance agreement with UMMC as part of Prime Site program

Two-day international Osteoarthritis Summit to be held in June 2011

Intellipharmaceutics provides update on generic version of Effexor XR

Endo subsidiary successfully completes tender offer for HealthTronics' outstanding common stock

ClinTec International CRO expands US based operations with launch of New York office

Researchers identify gene abnormality for most common congenital birth defect, clubfoot

Sun Pharma introduces generic rivastigmine capsules in U.S. market

Imbalance in neuroendocrine system linked to depression in MS patients: Study

University College London neurology professor becomes first recipient of Lord Brain Memorial Medal

New research identifies memory and brain scan as best tests for predicting Alzheimer's disease

Endo responds to FDA Complete Response letter for FORTESTA NDA

Eisai to commercialize lorcaserin for obesity and weight management in U.S.

Eisai signs agreement with Arena Pharmaceuticals GmbH to commercialize lorcaserin

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Gene diagnosis to be featured at 9th INT'L BIO FORUM & BIO EXPO JAPAN

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Neurology News and Research

Latest Neurology News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in